Literature DB >> 25938888

Impact of Regional Lymph Node Dissection on Disease Specific Survival in Adrenal Cortical Carcinoma.

N Saade1, C Sadler1, M Goldfarb2.   

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. The purpose of this study is to evaluate the impact of a more extensive regional lymph node dissection (LND) has on survival in ACC patients in the United States. Patients ≥ 15 years of age without distant metastases who underwent surgical intervention for primary ACC were identified from the SEER18 registry from 1988-2009. Patients were divided into 2 groups: having a regional LND (≥ 5 LNs removed) vs. no-LND (0-4 LNs removed). Overall survival (OS) and disease specific survival (DSS) were compared between groups. Of 259 patients with complete data on nodal resection, 243 (93.8%) underwent no-LND and 16 (6.2%) LND. There was no difference in age, sex, metastases, or ENSAT stage between groups. However, LND patients had larger tumors (p=0.004), and more frequently underwent en-bloc surgery (p=0.002). One- and 3-year OS and DSS did not differ between groups. In a cox regression model, performance of a regional LND did not significantly influence DSS. However, female gender (HR: 1.67, CI: 1.04-2.69, p=0.033) and later stage (stage III-HR: 4.78, CI: 1.14-20.00, p=0.032) or positive LNs (HR: 5.92, CI: 2.05-17.08, p=0.001) were risk factors for worse DSS. Regional LND may not improve DSS or OS in nonmetastatic ACC patients undergoing adrenalectomy. It remains controversial as an essential part of the surgical management for ACC and deserves further investigation in a larger, prospective study. However, regional LND should still be considered for staging and prognostic purposes and to standardize surgical care. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25938888     DOI: 10.1055/s-0035-1549877

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  9 in total

Review 1.  [Surgical strategies for non-metastatic adrenocortical carcinoma].

Authors:  N Rayes; M Quinkler; T Denecke
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

2.  Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study.

Authors:  Naris Nilubol; Dhaval Patel; Electron Kebebew
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

3.  Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma.

Authors:  Mechteld C de Jong; Radu Mihai; Shahab Khan
Journal:  World J Surg       Date:  2020-11-21       Impact factor: 3.352

4.  Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?

Authors:  Jon M Gerry; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason A Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2016-09-02       Impact factor: 5.344

5.  Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma.

Authors:  Javier Valero-Elizondo; Yuhree Kim; Jason D Prescott; Georgios A Margonis; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

6.  Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-19       Impact factor: 5.344

7.  The challenge to differentiate between sarcoma or adrenal carcinoma-an observational study.

Authors:  Eva M Dobrindt; Wolfgang Saeger; Hendrik Bläker; Martina T Mogl; Marcus Bahra; Johann Pratschke; Nada Rayes
Journal:  Rare Tumors       Date:  2021-12-10

Review 8.  Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Ther Adv Chronic Dis       Date:  2021-07-20       Impact factor: 5.091

Review 9.  Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma-A Systematic Review and Meta-Analysis.

Authors:  Anne Hendricks; Sophie Müller; Martin Fassnacht; Christoph-Thomas Germer; Verena A Wiegering; Armin Wiegering; Joachim Reibetanz
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.